VTX:NOVNNovartis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume11.21 million shsAverage Volume5.98 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlines Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. has a strategic alliance with Orion Corporation to manufacture topical nitric oxide-releasing product candidates. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.Read More Beat the Market (BTM) Rank™ 4.1 Analyst's Opinion Consensus RatingNovartis has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on 5 buy ratings, 6 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of CHF 92.77, Novartis has a potential upside of ∞ from its current price of CHF 0.Amount of Analyst CoverageNovartis has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.1 Community Rank Outperform VotesNovartis has received 251 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovartis has received 356 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovartis has received 58.65% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote “Outperform” if you believe NOVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNovartis does not currently pay a dividend.Dividend GrowthNovartis does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 4.1Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.24 out of 5 stars Industry, Sector and Symbol Stock Exchange VTX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolVTX:NOVN Previous Symbol CUSIPN/A CIKN/A Webwww.novartis.com Phone+41-61-3241111Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees47 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable NOVN Rates by TradingView Receive NOVN News and Ratings via Email Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter. Novartis (VTX:NOVN) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Novartis? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Novartis. What price target have analysts set for NOVN? 13 analysts have issued 1-year price objectives for Novartis' stock. Their forecasts range from CHF 70 to CHF 110. On average, they anticipate Novartis' stock price to reach CHF 92.77 in the next year. View analysts' price targets for Novartis. Has Novartis been receiving favorable news coverage? Media stories about NOVN stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novartis earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutNovartis. Who are some of Novartis' key competitors? Some companies that are related to Novartis include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Antibe Therapeutics (VBIZF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE), Canada House Wellness Group (CHV) and Cannabics Pharmaceuticals (CNBX). View all competitors. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Novartis (NVS), General Motors (GM), Iamgold (IAG), DigitalGlobe (DGI), Kraft Heinz (KHC), Mastercard (MA), Bank of America (BAC), Delta Air Lines (DAL), General Electric (GE) and SAP (SAP). Who are Novartis' key executives? Novartis' management team includes the following people: Mr. G. Kelly Martin, CEO & Director (Age 60)Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)Dr. Carri Geer, Sr. VP & CTO What is Novartis' stock symbol? Novartis trades on the VTX under the ticker symbol "NOVN." What is Novartis' official website? The official website for Novartis is www.novartis.com. How can I contact Novartis? Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111. This page was last updated on 5/28/2020 by MarketBeat.com Staff
